Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells was written by Kodama, E. N.; McCaffrey, R. P.; Yusa, K.; Mitsuya, H.. And the article was included in Biochemical Pharmacology in 1999.Related Products of 13146-72-0 The following contents are mentioned in the article:
The nucleoside analog cordycepin (3′-deoxyadenosine, 3′-dA) is substantially more cytotoxic to terminal deoxynucleotidyl transferase pos. (TdT+) leukemic cells than to TdT- leukemic cells in vitro in the presence of an adenosine deaminase inhibitor, deoxycoformycin (dCF), and has been considered as a therapeutic agent for TdT+ leukemia. The intracellular metabolism of 3′-dA was examined with HPLC, and the mechanism of its anti-TdT+ leukemic activity was analyzed. In the presence of dCF (2.5 μM), TdT+ leukemic cells (N = 5) were sensitive to the cytotoxic effect of 3′-dA, whereas TdT- (N = 6) cells were not. A high level of 3′-dA-5′-triphosphate (3′-dATP) formation was detected in TdT+ NALM-6 cells (67 pmol/106 cells) and TdT- K562 cells (49 pmol/106 cells) when cultured with 1 μM [3′-3H]-labeled 3′-dA. A substantial level of 3′-dATP was detected in TdT- HUT-102 cells (27 pmol/106 cells), whereas the level of 3′-dATP in TdT+ MOLT-4 cells was low (0.3 pmol/106 cells). The mean IC50 values of 3′-dA against phytohemagglutinin (PHA)-activated and resting peripheral blood mononuclear cells (PBM) (N = 5) were 8 and 32 μM, resp. There was a modest level of 3′-dATP (7 pmol/106 cells) in PHA-PBM, whereas a lower level of 3′-dATP was detected in resting PBM (2.5 pmol/106 cells). These data suggest that the presence of 3′-dATP is not sufficient for the antileukemic effect of 3′-dA, but that TdT positivity is essential, and that PBM are significantly less sensitive to the cytotoxicity of 3′-dA in vitro. Further development of 3′-dA as a potential antileukemic agent to treat patients with TdT+ leukemia is warranted. This study involved multiple reactions and reactants, such as 9-((2R,3R,5S)-3-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol (cas: 13146-72-0Related Products of 13146-72-0).
9-((2R,3R,5S)-3-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol (cas: 13146-72-0) belongs to tetrahydrofuran derivatives. Solid acid catalysis, and the advantages often associated with their use, have been proved equally efficient for the synthesis of tetrahydrofurans or furans. THF can also be synthesized by catalytic hydrogenation of furan. This allows certain sugars to be converted to THF via acid-catalyzed digestion to furfural and decarbonylation to furan, although this method is not widely practiced. THF is thus derivable from renewable resources.Related Products of 13146-72-0
13146-72-0;9-((2R,3R,5S)-3-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol;The future of 13146-72-0;New trend of C10H12N4O4 ;function of 13146-72-0